Gracell Biotechnologies Inc. | TalkMarkets | Page 1
No data available
No data available

People who follow this stock (2)

Latest Posts

About This Stock More About This Stock
Week In Review: Livzon In-Licenses GERD Therapy In $127 Million Agreement
Article By: ChinaBio® Today
Saturday, March 18, 2023 2:40 PM EDT
Livzon Pharmaceutical Group entered a $127.5 million agreement for China rights to a gastroesophageal reflux disease therapy from Onconic Therapeutics. Meanwhile, Gracell Biotech announced that it had entered an unusual global deal with Seagen.
In this article: GRCL Also: PFE, REGN, SGEN, CALT, IRON

Latest Tweets for $GRCL

No tweets yet!